Photocure ASA · OSL:PHO
Photocure ASA — Carnegie Nordic Healthcare Day 2017
22 slides from Photocure ASA's conference presentation, Dec 5, 2017
Slide 1: Photocure ASA Corporate Presentation
PHOTOCURE ASA CORPORATE PRESENTATION DECEMBER 2017 Ambaw Bellete President, Photocure Inc. and Head, US Cancer Commercial Operations
Slide 2: Disclaimer
DISCLAIMER The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various as
Slide 3: Photocure – Investment Highlights
PHOTOCURE – INVESTMENT HIGHLIGHTS Commercial-stage company focused Value building opportunities on Urology anticipated in next 12 – 24 months • Hexvix®/Cysview® for improved detection • Large untapped potential for and management of bladder cancer Hexvix/Cysview in existing and new ─ Improved detect
Slide 4: Hexvix/Cysview Update
Hexvix/Cysview Update
Slide 5: The Current State of Bladder Cancer
THE CURRENT STATE OF BLADDER CANCER Bladder cancer is 5TH most • Most expensive cancer : $96 - $187k / patient1 • 76,960 new US cases in 2016, 16,390 deaths common cancer in the EU / • Accounts for $3.7 billion in direct medical in US in 20163 4th most common cancer costs/year² • Lifetime risk of de
Slide 6: Improving Bladder Cancer Management
IMPROVING BLADDER CANCER MANAGEMENT BLC with Hexvix (EU) / Cysview (US) for improved View of Bladder with use of WLC detection and management of bladder cancer • Hexvix/Cysview is a colorless contrast solution that is used with a blue-light enabled cystoscope • First approved drug-device procedure;
Slide 7: Hexvix/Cysview a Global Specialty Brand
HEXVIX/CYSVIEW A GLOBAL SPECIALTY BRAND Increased Sales and Blue Light Cystoscopes In-Market Unit Sales • Sales revenues in 2016 increased YoY 11% to NOK 136M ($16.2M). YTD Q3 revenue increase YoY 10% to NOK 110M ($13.2M) • Sales revenues comprise: – Own sales of Hexvix in the Nordic region – Own sa
Slide 8: Cysview US Driving Accelerated Growth
Cysview US Driving Accelerated Growth
Slide 9: Cysview US Driving Accelerated Growth
CYSVIEW US DRIVING ACCELERATED GROWTH Grow Body of Expand Product Build Market Clinical Evidence & Execute Sales Plan Pipeline & Market Awareness Recommendation Opportunity • Educate surgeons and • On-going, real world • Expand sales teams, • Introduction of the BLFC develop advocates registry study
Slide 10: Building Awareness: Inclusion in National Guidelines
BUILDING AWARENESS: INCLUSION IN NATIONAL GUIDELINES Transforming Clinical Practice • US Guidelines: Use of Blue Light Cystoscopy with Hexvix/Cysview receives highest level of recommendation in the new AUA/SUO bladder cancer guideline – Recommended based on the large body of evidence supporting both
Slide 11: Execute Sales Plan: Maximizing Sales Efficiency Targeting Top 25 Markets
EXECUTE SALES PLAN: MAXIMIZING SALES EFFICIENCY TARGETING TOP 25 MARKETS Top 25 markets – TURBT rank Example anchor accounts Comments Totals (inpatient & outpatient TURBT Metropolitan statistical area procedures*): Total • Focus efforts to establish and build New York, Newark, Jersey 21,284 Cysview
Slide 12: Expansion into Larger Segments: Market Opportunity in Surveillance Segment
EXPANSION INTO LARGER SEGMENTS: MARKET OPPORTUNITY IN THE SURVEILLANCE SEGMENT • Expansion with Blue Light Flexible Cystoscopy with Cysview • For office settings (surveillance and first diagnostic) that utilize flexible cystoscopes Segments of the Global Cystoscopy Market CURRENT TURBT PROCEDURES TU
Slide 13: Expansion into Larger Segments: Phase 3 Clinical Trial Results at AUA 2017
EXPANSION INTO LARGER SEGMENTS: PHASE 3 CLINICAL TRIAL RESULTS REPORTED AT AUA 2017 Overview Endpoints Conclusion • Compare use of Blue Light • Primary endpoint - the rate at • BLFCC significantly improves the Cystoscopy with Cysview which malignancy is detected with detection of patients with recur
Slide 14: Supplemental New Drug Application – Priority Review
EXPANSION INTO LARGER SEGMENTS: SUPPLEMENTAL NEW DRUG APPLICATION – PRIORITY REVIEW • Expanded indications to include combination of Cysview with KARL STORZ Flexible Videoscope System in addition to current Rigid Scope System targeting surveillance cystoscopies of patients diagnosed NMIBC – Of the t
Slide 15: US Medicare Reimbursement of Additional USD 1,000 per TURBT from 2018
US MEDICARE REIMBURSEMENT OF AN ADDITIONAL USD 1,000 PER TURBT FROM 2018* Medicare (~55% of TURBT) Private payer (~45% of TURBT) • Procedure fee for cystoscopy • Procedure fee for cystoscopy • Cysview paid at contracted rate (ASP** +6 to Cystoscopy • Cysview paid at ASP** +6% 15%) • No change from 2
Slide 16: Cysview US Continued Strong Momentum
CYSVIEW US CONTINUED STRONG MOMENTUM • Photocure own sales revenue in the US in 3Q increased 45% YoY – Driven by YoY in-market volume growth of 39% in third quarter – 6th quarter with QoQ sales revenue growth in the US, despite seasonality • Permanent Blue Light Cystoscope placements of 96 at the en
Slide 17: Non-Urology Pipeline
Non-Urology Pipeline
Slide 18: Cevira & Visonac Phase 3 Ready Products with Significant Sales Potential
CEVIRA & VISONAC PHASE 3 READY PRODUCTS WITH SIGNIFICANT SALES POTENTIAL • Cevira - Breakthrough single use and fully integrated drug- device technology to satisfy high need for novel non-surgical therapies to treat global epidemic of HPV/HSIL populations • Visonac – Novel topical non-antibiotic/non
Slide 19: Financials
Financials
Slide 20: Key Financials – YTD Q3 2017
KEY FINANCIALS – YTD Q3 2017 • Q3 Hexvix/Cysview revenues driven by US Income Statement - Segments ─ US sales +46%. Installed base of BLC at 96 (YE 2016: 83) MUSD YTD '17 YTD '16 Change ─ Nordic revenues improved from a slow start of the Commercial Franchise year. 4% increase YTD and 8% in Q3. Previ
Slide 21: Photocure – Investment Highlights
PHOTOCURE – INVESTMENT HIGHLIGHTS Commercial-stage company focused Value building opportunities on Urology anticipated in next 12 – 24 months • Hexvix®/Cysview® for improved detection • Large untapped potential for and management of bladder cancer Hexvix/Cysview in existing and new ─ Improved detect
Slide 22: Contact Information
CONTACT INFORMATION Ambaw Bellete President, Photocure Inc. and Head, US Cancer Commercial Operations Tel: +1 609 759 6500 [email protected] Erik Dahl Chief Financial Officer Tel: + 47 450 55 000 [email protected] 22